SG Americas Securities LLC Sells 61,749 Shares of Baxter International Inc. $BAX

SG Americas Securities LLC cut its stake in Baxter International Inc. (NYSE:BAX) by 83.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,345 shares of the medical instruments supplier’s stock after selling 61,749 shares during the period. SG Americas Securities LLC’s holdings in Baxter International were worth $374,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in BAX. Dodge & Cox raised its stake in shares of Baxter International by 2.1% in the 1st quarter. Dodge & Cox now owns 51,458,925 shares of the medical instruments supplier’s stock valued at $1,761,439,000 after purchasing an additional 1,081,631 shares during the period. Geode Capital Management LLC grew its holdings in shares of Baxter International by 2.6% during the second quarter. Geode Capital Management LLC now owns 12,882,960 shares of the medical instruments supplier’s stock worth $388,416,000 after buying an additional 326,652 shares in the last quarter. Park National Corp OH raised its position in Baxter International by 2,691.4% in the 2nd quarter. Park National Corp OH now owns 219,512 shares of the medical instruments supplier’s stock valued at $6,647,000 after buying an additional 211,648 shares during the last quarter. Cooke & Bieler LP raised its position in Baxter International by 10.8% in the 2nd quarter. Cooke & Bieler LP now owns 1,750,510 shares of the medical instruments supplier’s stock valued at $53,005,000 after buying an additional 170,560 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec bought a new stake in Baxter International in the 1st quarter valued at approximately $5,349,000. Institutional investors own 90.19% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on BAX. UBS Group decreased their price target on shares of Baxter International from $24.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, October 31st. Stifel Nicolaus reduced their target price on shares of Baxter International from $25.00 to $22.00 in a report on Friday, October 31st. Citigroup decreased their target price on shares of Baxter International from $26.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, October 31st. Jefferies Financial Group lowered their price target on shares of Baxter International from $25.00 to $21.00 and set a “hold” rating on the stock in a research note on Thursday, October 30th. Finally, Argus downgraded shares of Baxter International from a “buy” rating to a “hold” rating in a research note on Friday, October 31st. Two investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $23.70.

Baxter International Price Performance

Shares of BAX opened at $18.77 on Friday. The company has a market cap of $9.65 billion, a price-to-earnings ratio of -62.55, a PEG ratio of 0.73 and a beta of 0.57. Baxter International Inc. has a 1-year low of $17.40 and a 1-year high of $37.74. The company’s fifty day simple moving average is $20.80 and its 200 day simple moving average is $25.22. The company has a current ratio of 2.30, a quick ratio of 1.49 and a debt-to-equity ratio of 1.30.

Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, October 30th. The medical instruments supplier reported $0.69 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.09. Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. The firm had revenue of $2.84 billion during the quarter, compared to analysts’ expectations of $2.88 billion. During the same quarter last year, the company posted $0.80 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS. FY 2025 guidance at 2.350-2.400 EPS. On average, research analysts forecast that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Baxter International Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 2nd. Shareholders of record on Friday, November 28th will be given a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend is Friday, November 28th. Baxter International’s payout ratio is -6.06%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.